Diabesity Rounds

Orforglipron lowered apnoea-hypopnoea index in two 52-week phase 3 OSA trials

In two placebo-controlled phase 3 trials in adults with moderate to severe obstructive sleep apnoea and obesity or overweight, oral orforglipron reduced AHI more than placebo, with more gastrointestinal events.

At a glance

  • In both trials, AHI fell more with orforglipron than with placebo at 52 weeks (difference -13.2 in trial 1 and -12.0 in trial 2, events/h).
  • Six of 7 key secondary end points were statistically significant, favouring orforglipron.
  • Gastrointestinal events were more frequent with orforglipron (68.0% and 70.6%) than with placebo (37.4% and 36.6%).

The study

This report covers two 52-week, phase 3, multicentre, double-blind, placebo-controlled randomised trials, published in JAMA (ATTAIN-OSA). They were run at 66 sites in the US, Argentina, Brazil, China, Czech Republic, Germany, Japan, Mexico and Taiwan. India was not among the countries listed.

Adults had moderate to severe obstructive sleep apnoea (OSA) and a BMI of 27 or higher. Trial 1 enrolled patients not using positive airway pressure (PAP). Trial 2 enrolled patients using PAP. Patients were randomised 1:1 to once-daily oral orforglipron, at the maximum tolerated dose, or to placebo.

The primary end point was the change in apnoea-hypopnoea index (AHI, events/h) from baseline to week 52. There were seven key secondary end points, controlled for multiplicity. They included sleep apnoea-specific hypoxic burden, the PROMIS Short Form Sleep-Related Impairment T-score and high-sensitivity C-reactive protein.

What they found

Trial 1 randomised 363 patients (mean age 48.4 years, BMI 37.4, AHI 50.7 events/h, 31.4% female). Trial 2 randomised 349 patients (mean age 51.1 years, BMI 38.6, AHI 57.6 events/h, 26.9% female).

Results below use the treatment regimen estimand. AHI fell in both groups in both trials, and it fell more with orforglipron.

  • Trial 1: the mean AHI change was -17.8 with orforglipron and -4.5 with placebo. The difference was -13.2 (95% CI, -17.7 to -8.7; P < .001).
  • Trial 2: the mean AHI change was -17.3 with orforglipron and -5.3 with placebo. The difference was -12.0 (95% CI, -17.1 to -6.9; P < .001).

Of the 7 key secondary end points, 6 were statistically significant, favouring orforglipron. The abstract does not say which one was not significant, and it does not give the individual secondary results.

Gastrointestinal events were the most common adverse events. In trial 1 they occurred in 123 participants (68.0%) on orforglipron and 68 (37.4%) on placebo. In trial 2 they occurred in 125 participants (70.6%) on orforglipron and 63 (36.6%) on placebo.

How much weight to give it

The design is strong. Both trials were randomised, double-blind and placebo-controlled, and both showed the same direction of effect with confidence intervals that did not include zero. The authors concluded that the results provide evidence for the potential use of oral orforglipron to improve sleep-disordered breathing in adults with moderate to severe OSA and obesity or overweight.

Some limits apply. AHI is a measure of disease severity, not a hard outcome. The abstract does not report effects on cardiovascular events or other long-term outcomes. It does not report funding, treatment discontinuations, serious adverse events or results by sex or region. Mean BMI was 37.4 in trial 1 and 38.6 in trial 2, so the findings may not apply equally to people with a lower BMI. The results come from a 52-week period, so longer-term effects are unknown. Please read the full paper for these details.

For your clinic

These data suggest that oral orforglipron reduced AHI compared with placebo in adults with moderate to severe OSA and obesity or overweight. This was seen both in patients not using PAP (trial 1) and in those using PAP (trial 2).

Gastrointestinal events were common, so tolerability should be part of any future discussion. Before changing practice, read the full paper, including the safety data, and wait for national guidance.

Source

Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).

Malhotra A, Gottlieb DJ, Woehrle H et al.. JAMA. 9 November 2026

Read the source · DOI 10.1001/jama.2026.24080

Cite this report: Diabesity Rounds. Orforglipron lowered apnoea-hypopnoea index in two 52-week phase 3 OSA trials. 2026. doi:10.5281/zenodo.24236965

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on glp-1 and incretin drugs

Go deeper